Today’s Top Three in Pharma 020209

The FDA gives a hint of hope for the long-delayed Eli Lilly/Daiichi Sankyo drug prasugrel. Burrow deep inside this 357-page FDA document just posted online, and you’ll find this jargony but significant sentence: The Division recommends approval of prasugrel for reduction of myocardial infarction in patients with ACS who are managed with PCI.

Glaxo the latest Big Pharma to announce major upcoming cuts – British drugs company GlaxoSmithKline Plc.  is set to announce about 6,000 job losses when it posts results on Thursday, the Sunday Telegraph newspaper said. The cuts by Glaxo, the world’s second largest drugs company after U.S. group Pfizer, are part of Chief Executive Andrew Witty’s strategy to meet the challenges facing the industry, including increased competition from generic drug makers, the British newspaper said.

Teva gets FDA OK for generic version of J&J‘s Risperdal. And, Takeda gets approval for new GERD drug Kapidex.

——

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS